
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Jun 23
Feb 23
Innoplexus wins Horizon Interactive Gold Award for Curia App
Read MorePune, India, February 13, 2020 – Innoplexus Consulting Services Private Limited, a subsidiary of Innoplexus AG, is delighted to have been awarded ISO/IEC 27001:2013 certification, a global standard for reducing the risk and improving the security of data. Innoplexus has been committed to achieving the highest levels of security compliance. This accreditation further cements Innoplexus’ efforts to maximize protection of its clients’ and key stakeholders’ valuable data and information assets.
Commitment to Continuous Improvement
Innoplexus is committed to continually improving its Information Security Management System (ISMS). The implementation team based in Pune, India, underwent an extensive company-wide audit that included a process-based approach for establishing, implementing, operating, monitoring, maintaining, and improving ISMS.
ISO is one of the most well-respected global standards. Innoplexus was audited by Perry Johnson Registrars and was presented with its certificate on 13th February 2020.
Innoplexus Consulting Services Managing director, Abhijit Keskar said, “Achieving ISO/IEC 27001:2013 certification is fantastic news and means our customers have complete assurance that their confidential information is secure with us.” He thanked the project team adding, “It proves theirs and the company’s commitment to ensuring the best ISMS for our clients.”
Innoplexus is a leading global AI-technology solution provider with over 300 employees and 100+ patent applications including 12 grants in artificial intelligence, machine learning, and blockchain technologies. Innoplexus applies its proprietary tech stack at all stages of the drug development value chain, through smart Data as a Service (DaaS) and Continuous Analytics as a Service (CAaS) solutions. These solutions can generate real-time insights from hundreds of terabytes of structured and unstructured private and public data, thereby facilitating continuous, informed decision-making for its customer base. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany, with offices in Pune, India, as well as Iselin, and San Francisco, United States.
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trialsBOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary…
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific…
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years…
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be…